OFEV: payments to doctors
Payments that named OFEV as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $16.8M
- Providers
- 26,227
- Transactions
- 168,234
- Average per transaction
- $100
The per-transaction average — $100 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 26,227 providers the average total is $639, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Boehringer Ingelheim | $14,178,864 | 84.6% |
| Boehringer Ingelheim International GmbH | $2,240,153 | 13.4% |
| Boehringer Ingelheim RCV GmbH & Co KG | $73,795 | 0.4% |
| Boehringer Ingelheim Italia S.p.a. | $61,891 | 0.4% |
| Boehringer Ingelheim Pharma GmbH & Co.kg | $59,436 | 0.4% |
| Boehringer Ingelheim Pty Ltd | $50,763 | 0.3% |
| Boehringer Ingelheim Do Brasil Quimica E Farmaceutical Ltda. | $25,707 | 0.2% |
| Boehringer Ingelheim Taiwan Ltd. | $24,199 | 0.1% |
| Boehringer Ingelheim Mexico SA De CV | $11,337 | 0.1% |
| Boehringer Ingelheim Espana S.A. | $10,000 | 0.1% |
| Boehringer Ingelheim Malaysia Sdn. Bhd. | $8,415 | 0.1% |
| Nippon Boehringer Ingelheim Co., Ltd. | $3,468 | 0.0% |
| Boehringer Ingelheim Singapore Pte. Ltd. | $3,125 | 0.0% |
| Boehringer Ingelheim MENA (scientific Office) Fz-llc | $2,800 | 0.0% |
| Boehringer Ingelheim (phil.) Inc. | $2,500 | 0.0% |